Coseropositivity to Tick-Borne Pathogens Among Patients Suspected to Have Lyme Disease Authors: Yonghong Li, Carmen H. Tong, Tara S. Givens, Ross M. Boyce Published: 2026 ABSTRACT This cohort study investigates codetection of Borrelia burgdorferi and other tick-borne pathogens in patients being tested for tick-borne disease. Introduction Lyme disease (LD), the most frequently reported vector-borne disease in the US,1 is caused by infection with Borrelia burgdorferi sensu lato and transmitted through the bite of Ixodes ticks. However, Ixodes ticks also harbor other pathogens, including Anaplasma phagocytophilum and the malaria-like parasite Babesia microti.2,3 Co-infections with other pathogens can complicate diagnosis and treatment.4,5,6 However, the clinical burden of co-infections is evolving and frequently underappreciated. We sought to investigate patterns and frequencies of codetection of antibodies against B burgdorferi and other tick-borne pathogens in patients undergoing testing for tick-borne disease. Methods This cohort study was reviewed by the WCG Institutional Review Board, an independent ethical review board, and deemed to be exempt under federal regulation 45 CFR §46.104(d)(4). Reporting of this study follows the STROBE reporting guideline. We queried the Quest Diagnostics test database for individuals who had undergone tick-borne disease serological panel testing during the 5 years from January 2021 to December 2025 (eFigure and eMethods in Supplement 1). Data used were deidentified as required by the HIPAA Privacy Rule (45 CFR §164.514). Results without associated information on age, sex, or state of residence were excluded. We restricted the analysis to the first test from unique individuals identified in the period. We performed descriptive analysis of the data in Microsoft 365 (Microsoft Corp), and we used a log-binomial regression model to estimate seropositivity ratio and 95% CIs, with adjustment for age, sex, testing month, and region, using SAS version 9.4 (SAS Institute). Statistical testing was 2-sided, with P < .05 considered statistically significant. Results We included 193 260 individuals in the study cohort (108 878 female [56.3%] and 84 382 male [43.7%]; median [IQR] age, 51 [35-64] years). Most were adults (aged ≥18 years; 92.4%) and resided in the Northeast region (70.6%), and 40.7% were tested between June and August. Seropositivity was observed in 9609 individuals (5.0%) for B burgdorferi, 6003 individuals (3.1%) for A phagocytophilum, 6497 individuals (3.4%) for B microti, and 1980 individuals (1.0%) for Ehrlichia spp. Together, 13 014 individuals tested (6.7%) were seropositive for at least 1 non-LD tick-borne pathogen. Compared with individuals who were seronegative for B burgdorferi, individuals who were seropositive for B burgdorferi were more likely to be seropositive for A phagocytophilum, B microti, and Ehrlichia spp in all 4 US Census regions (Figure 1). While seropositivity for another tick-borne pathogen was observed in 5.5% of tested individuals who were seronegative for B burgdorferi, it was observed in 29.5% of individuals who were seropositive for B burgdorferi. The seropositivity ratio for other tick-borne pathogens in individuals with vs without laboratory evidence of LD was 4.46 (95% CI, 4.30-4.63; P < .001). Compared with individuals in other regions, individuals who were seropositive for B burgdorferi in the Northeast region tested seropositive more frequently for non-LD tick-borne pathogens (31.1% vs 13.6%-16.6%). Bar Graph of Regional Seropositivity Rates of Tick-Borne Pathogens Rates are shown in panels A through D stratified by laboratory evidence of Lyme disease (LD) status (LD positive [LD+] vs LD negative [LD−]). The number of individuals in the LD+ group was 8601 in Northeast, 571 in Midwest, 393 in South, and 44 in West regions, and the number of individuals in the LD− group was 127 895 in Northeast, 24 581 in Midwest, 27 901 in South, and 3274 in West regions. A phagocytophilum indicates Anaplasma phagocytophilum; B microti, Babesia microti. The IgM and IgG distribution heatmap shows an apparent antibody-type correlation among coseropositive individuals (Figure 2). Correlation with B burgdorferi IgM was observed across IgM of all other pathogens. B burgdorferi IgG was also correlated with B microti and A phagocytophilium IgG but not with Ehrlichia IgG. Heatmap of Antibody-Detection Profiles Among Individuals Who Were Coseropositive The 3 × 3 grids in panels A through C show the distribution of IgM and IgG antibodies detected among individuals who were coseropositive. Shading gradients represent the frequency of individuals appearing in each joint antibody category, with annotated values indicating absolute counts. A phagocytophilum indicates Anaplasma phagocytophilum; B burgdorferi, Borrelia burgdorferi; B microti, Babesia microti. Discussion In this large, national cohort study, individuals with laboratory evidence of LD had a higher likelihood of seropositivity for other tick-borne pathogens, most notably Anaplasma and Babesia. The strong association between seropositivity for B burgdorferi, A phagocytophilum, and B microti is consistent with underlying biology given that all 3 are transmitted by Ixodes scapularis ticks.2,3 The strong correlation between seropositivity for B burgdorferi and Ehrlichia, traditionally thought to be transmitted by Amblyomma americanum, is notable. This could be associated with cumulative exposure to multiple species of ticks driven by individual behaviors (eg, occupation, outdoor recreation), low-level cross-reactivity with Anaplasma, or exposure in some regions to Ehrlichia muris eauclairensis, which is transmitted by Ixodes scapularis ticks, unlike other Ehrlichia species. This study has limitations, including unknown clinical indications driving test ordering and unknown disease stage (eg, acute or chronic symptoms), a lack of molecular testing, and an unknown seropositivity level for non-LD tick-borne pathogens, as well as potential false-positive and false-negative serological results. False positivity may be more common with the less specific IgM component of serologic assays, which may partly explain the higher rates of coseropositivity observed across pathogens. Furthermore, coseropositivity does not prove active co-infection, and a standard 2-tier testing algorithm has lower sensitivity in early stage LD.7 While somewhat expected,8,9,10 the increased seropositivity for A phagocytophilum and B microti among individuals with laboratory evidence of LD reinforces the need for clinicians to maintain a high index of suspicion for non-LD tick-borne pathogens, particularly in the Northeast region. This clinical vigilance is especially critical given the highest rate of coseropositivity to Babesia, which is not susceptible to doxycycline, the first-line treatment for LD.